<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311359</url>
  </required_header>
  <id_info>
    <org_study_id>PV-BO</org_study_id>
    <nct_id>NCT04311359</nct_id>
  </id_info>
  <brief_title>A Pharmacovigilance Study of Brain Oedema</brief_title>
  <official_title>A Pharmacovigilance Study of Brain Oedema in the Food and Drug Administration Adverse Event Reporting System Using Data Mining Algorithms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Peshawar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Peshawar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Literature reports the development of brain oedema following the use of certain drugs.
      Therefore, this study aims to present a comprehensive disproportionality analysis of brain
      oedema cases reported to the Food and Drug Administration Adverse Event Reporting System
      (FAERS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brain oedema is a serious neurological condition, as it possesses a significant impact on the
      functional abilities of an individual by causing irreversible brain damage and potentiates
      the risk of mortality. Apart from a number of medical conditions causing brain oedema,
      evidence suggests the association of various drugs with brain oedema. Therefore, this study
      aims to provide a comprehensive disproportionality analysis of the drug-induced brain oedema
      reports in the FAERS database.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">November 10, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Identification of drugs associated with Brain Oedema</measure>
    <time_frame>Cases reported to the FAERS database since inception till 31/03/2019</time_frame>
    <description>The search includes MedDRA (v-22) Preferred Term, &quot;Brain Oedema (MedDRA code: 10048962) for the identification of all Brain Oedema case reports and drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of signals of Brain Oedema</measure>
    <time_frame>Cases reported to the FAERS database since inception till 31/03/2019</time_frame>
    <description>Signal detection using disproportionality analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stratification of new signals with respect to age</measure>
    <time_frame>Cases reported to the FAERS database since inception till 31/03/2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stratification of new signals with respect to gender</measure>
    <time_frame>Cases reported to the FAERS database since inception till 31/03/2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trends of Brain Oedema reports in FAERS database</measure>
    <time_frame>Cases reported to the FAERS database since inception till 31/03/2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trends of Brain Oedema reports in Google searches</measure>
    <time_frame>Cases reported to the FAERS database since inception till 31/03/2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the population of patients having Brain Oedema</measure>
    <time_frame>Cases reported to the FAERS database since inception till 31/03/2019</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9524</enrollment>
  <condition>Brain Edema</condition>
  <condition>Brain Edema Caused by Drugs</condition>
  <arm_group>
    <arm_group_label>Group/Cohort</arm_group_label>
    <description>Brain Oedema induced by drugs reported to the FAERS database from inception till first quarter of 2019</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drugs, Generic</intervention_name>
    <description>All drugs having 19 or more Brain Oedema cases reported to the FAERS database</description>
    <arm_group_label>Group/Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presented with brain oedema treated for any disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Brain Oedema cases reported in the FAERS database till 31/03/2019

          -  Adverse event reported was included using the MedDRA term: Brain Oedema

        Exclusion Criteria:

          -  Drugs with less than 19 brain oedema reports
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Peshawar</name>
      <address>
        <city>Peshawar</city>
        <state>KPK</state>
        <zip>25000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Peshawar</investigator_affiliation>
    <investigator_full_name>Mohammad Ismail</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

